1st New Schizophrenia Drug in Decades
Cobenfy: The First New Schizophrenia Drug in Decades
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other antipsychotics.
FDA Approves groundbreaking drug for schizophrenia treatment
Cobenfy (xanomeline and trospium chloride) capsules are the first antipsychotic drug approved to target cholinergic receptors. All other treatments available for schizophrenia tar
Experts hail new schizophrenia drug Cobenfy as a game-changer, the ‘first of its kind’
Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer side effects.
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely different way from existing medications for schizophrenia, which is building excitement and enthusiasm among doctors and patients alike.
In a Victory for the Free Market, FDA Approves New Schizophrenia Drug
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical company.
FDA approves Cobenfy, a first-in-class schizophrenia drug
The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment. The drug was developed by Karuna Therapeutics, which was bought by Bristol Myers Squibb (BMS) last year for $14 billion.
FDA Approves the First New Type of Schizophrenia Drug in Decades
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle movement, and sedation — that can cause patients to discontinue treatment.
Breakthrough in Schizophrenia Treatment: FDA Approves Cobenfy
New drug offers hope for patients with Schizophrenia that has long eluded effective treatment. Read on to know more.
MyChesCo on MSN32m
FDA Approves Cobenfy, Pioneering New Approach to Schizophrenia Treatment
The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of ...
ScienceAlert1h
First New Schizophrenia Treatment in Decades a Much-Needed Alternative
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...
McKnight's Long-Term Care News3h
Schizophrenia treatment offers alternative with fewer side effects
The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major ...
Valley News Live6h
FDA approves new drug for schizophrenia, described as a potential ‘game changer’
The US Food and Drug Administration (FDA) recently approved a new medication treatmeant, called Cobenfy, which is a ...
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
WFAE3d
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Bristol Cobenfy approval draws optimism from Street, though with caveats
The U.S. FDA's approval Thursday of Bristol Myers Squibb's (NYSE:BMY) novel antipsychotic Cobenfy (xanomeline and trospium ...
Coventry need more 'grit' to end tough start - Sheaf
Coventry City captain Ben Sheaf is "sure" the Sky Blues will turn their poor start to the season around if they can find a ...